Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment

Woochan Hyung, Hyunjoo Ko, Joseph Park, Eunkyung Lim, Bae Park Sung, Young Joon Park, Geun Yoon Ho, Suck Suh Jin, Seungjoo Haam, Yong Min Huh

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Hyaluronic acid (HA) coated drug carriers (HCDCs) were successfully synthesized by chemical conjugation method for targeted delivery of doxorubicin (DOX) as a prototype anticancer drug to CD44 expressed human breast cancer cell. From XPS analysis, the HCDCs by conjugation methods demonstrated the superior HA fixation amount and colloidal stability compared with the nanoparticles by nanoprecipitation. The cytotoxicity of the HCDCs formulation accessed by the MTT assay against the higher CD44 expressed cell line (MDA-MB-231) and lower CD44 expressed cell line (ZR-75-1) human breast cancer cell lines demonstrated that the HCDCs formulation exhibited excellent tumoricidal effect and their affinity to cancer cells was predominant. The in vitro drug release profile of the HCDCs showed sustained release behavior and after 14 days, 80% of the encapsulated DOX was released due to a high release rate of DOX from HCDCs. We synthesized that HCDCs have therapeutic potentials of cancer as a target specific fashion by increasing the tumoricidal efficacy of targeted cancer cells while reducing their cytotoxicity of non-targeted cells to minimize the side effect.

Original languageEnglish
Pages (from-to)442-454
Number of pages13
JournalBiotechnology and Bioengineering
Volume99
Issue number2
DOIs
Publication statusPublished - 2008 Feb 1

Fingerprint

Hyaluronic acid
Drug Carriers
Oncology
Hyaluronic Acid
Cells
Breast Neoplasms
Doxorubicin
Drug Compounding
Cytotoxicity
Cell Line
Therapeutics
Neoplasms
Assays
Pharmaceutical Preparations
Nanoparticles
X ray photoelectron spectroscopy

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Hyung, Woochan ; Ko, Hyunjoo ; Park, Joseph ; Lim, Eunkyung ; Sung, Bae Park ; Park, Young Joon ; Ho, Geun Yoon ; Jin, Suck Suh ; Haam, Seungjoo ; Huh, Yong Min. / Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment. In: Biotechnology and Bioengineering. 2008 ; Vol. 99, No. 2. pp. 442-454.
@article{c580c0a1d2b047d5b22616f362e3f930,
title = "Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment",
abstract = "Hyaluronic acid (HA) coated drug carriers (HCDCs) were successfully synthesized by chemical conjugation method for targeted delivery of doxorubicin (DOX) as a prototype anticancer drug to CD44 expressed human breast cancer cell. From XPS analysis, the HCDCs by conjugation methods demonstrated the superior HA fixation amount and colloidal stability compared with the nanoparticles by nanoprecipitation. The cytotoxicity of the HCDCs formulation accessed by the MTT assay against the higher CD44 expressed cell line (MDA-MB-231) and lower CD44 expressed cell line (ZR-75-1) human breast cancer cell lines demonstrated that the HCDCs formulation exhibited excellent tumoricidal effect and their affinity to cancer cells was predominant. The in vitro drug release profile of the HCDCs showed sustained release behavior and after 14 days, 80{\%} of the encapsulated DOX was released due to a high release rate of DOX from HCDCs. We synthesized that HCDCs have therapeutic potentials of cancer as a target specific fashion by increasing the tumoricidal efficacy of targeted cancer cells while reducing their cytotoxicity of non-targeted cells to minimize the side effect.",
author = "Woochan Hyung and Hyunjoo Ko and Joseph Park and Eunkyung Lim and Sung, {Bae Park} and Park, {Young Joon} and Ho, {Geun Yoon} and Jin, {Suck Suh} and Seungjoo Haam and Huh, {Yong Min}",
year = "2008",
month = "2",
day = "1",
doi = "10.1002/bit.21578",
language = "English",
volume = "99",
pages = "442--454",
journal = "Biotechnology and Bioengineering",
issn = "0006-3592",
publisher = "Wiley-VCH Verlag",
number = "2",

}

Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment. / Hyung, Woochan; Ko, Hyunjoo; Park, Joseph; Lim, Eunkyung; Sung, Bae Park; Park, Young Joon; Ho, Geun Yoon; Jin, Suck Suh; Haam, Seungjoo; Huh, Yong Min.

In: Biotechnology and Bioengineering, Vol. 99, No. 2, 01.02.2008, p. 442-454.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment

AU - Hyung, Woochan

AU - Ko, Hyunjoo

AU - Park, Joseph

AU - Lim, Eunkyung

AU - Sung, Bae Park

AU - Park, Young Joon

AU - Ho, Geun Yoon

AU - Jin, Suck Suh

AU - Haam, Seungjoo

AU - Huh, Yong Min

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Hyaluronic acid (HA) coated drug carriers (HCDCs) were successfully synthesized by chemical conjugation method for targeted delivery of doxorubicin (DOX) as a prototype anticancer drug to CD44 expressed human breast cancer cell. From XPS analysis, the HCDCs by conjugation methods demonstrated the superior HA fixation amount and colloidal stability compared with the nanoparticles by nanoprecipitation. The cytotoxicity of the HCDCs formulation accessed by the MTT assay against the higher CD44 expressed cell line (MDA-MB-231) and lower CD44 expressed cell line (ZR-75-1) human breast cancer cell lines demonstrated that the HCDCs formulation exhibited excellent tumoricidal effect and their affinity to cancer cells was predominant. The in vitro drug release profile of the HCDCs showed sustained release behavior and after 14 days, 80% of the encapsulated DOX was released due to a high release rate of DOX from HCDCs. We synthesized that HCDCs have therapeutic potentials of cancer as a target specific fashion by increasing the tumoricidal efficacy of targeted cancer cells while reducing their cytotoxicity of non-targeted cells to minimize the side effect.

AB - Hyaluronic acid (HA) coated drug carriers (HCDCs) were successfully synthesized by chemical conjugation method for targeted delivery of doxorubicin (DOX) as a prototype anticancer drug to CD44 expressed human breast cancer cell. From XPS analysis, the HCDCs by conjugation methods demonstrated the superior HA fixation amount and colloidal stability compared with the nanoparticles by nanoprecipitation. The cytotoxicity of the HCDCs formulation accessed by the MTT assay against the higher CD44 expressed cell line (MDA-MB-231) and lower CD44 expressed cell line (ZR-75-1) human breast cancer cell lines demonstrated that the HCDCs formulation exhibited excellent tumoricidal effect and their affinity to cancer cells was predominant. The in vitro drug release profile of the HCDCs showed sustained release behavior and after 14 days, 80% of the encapsulated DOX was released due to a high release rate of DOX from HCDCs. We synthesized that HCDCs have therapeutic potentials of cancer as a target specific fashion by increasing the tumoricidal efficacy of targeted cancer cells while reducing their cytotoxicity of non-targeted cells to minimize the side effect.

UR - http://www.scopus.com/inward/record.url?scp=38449099566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449099566&partnerID=8YFLogxK

U2 - 10.1002/bit.21578

DO - 10.1002/bit.21578

M3 - Article

C2 - 17625788

AN - SCOPUS:38449099566

VL - 99

SP - 442

EP - 454

JO - Biotechnology and Bioengineering

JF - Biotechnology and Bioengineering

SN - 0006-3592

IS - 2

ER -